麝香保心丸治疗老年慢性稳定型心绞痛伴高脂血症的临床观察
|
摘要
目的:观察麝香保心丸治疗老年慢性稳定型心绞痛伴高脂血症的临床疗效,并对其部分作用机理进行初步探讨。方法:将60例符合标准的老年慢性稳定心绞痛及中医胸痹,痰瘀互结证患者的随机分为对照组30例,试验组30例。对照组给予单硝酸异山梨酯治疗,试验组予麝香保心丸治疗,观察治疗前及治疗3月、6月时疾病疗效、中医症候疗效、硝酸甘油疗效、心电图疗效以及对血脂、Hs-CRP、FIB的影响。结果:临床研究表明,试验组6月疾病疗效优于对照组(P<0.05),有效率为83.4%;试验组3月、6月中医症候疗效均优于对照组(P<0.05),有效率分别为73.3%和86.7%;实验组6月硝酸甘油疗效明显优于对照组(P<0.05),有效率为86.7%;试验组与对照组心电图疗效无统计学差异(P>0.05);试验组TC、LDL-C及FIB降低幅度均明显优于对照组(P<0.05)。结论:麝香保心丸对老年慢性稳定型心绞痛伴高脂血症(胸痹,痰瘀互结型)治疗作用确切,并证明其能明显降低冠心病的部分危险因素。
Objective: To observe the clinical effects of the elderly chronic stable angina with hyperlipidemia treated by the Shexiang Baoxin pills. Methods: 60 cases met the standards of elderly chronic stable angina patients with hyperlipidemia(XiongBi ,phlegm and blood stasis mixed type) were randomly divided into 30 cases of the Control Group and 30 cases of the Study Group. The Control Group was treated with the Isosorbide-5-Mononitrat and Study Group was treated with the Shexiang Baoxin pills .After 3 months and 6 months there should be comparisons between the two groups ,namely ,the improvement of disease effects ,TCM effects ,the nitroglycerin decrease rate and its effects ,the ECG effects and the blood lipid treatment effects ,Hs-CRP and FIB .Results: Clinical observations have shown that the Study Group can significantly improve the 6 months disease treatment effects (P<0.05), and the efficacy of the Study Group was 83.4% ;the 6 months nitroglycerin treatment effects of the Study Group was better than the Control Group(P<0.05) ,the efficacy of the Study Group was 86.7%; the ECG effects of the Study Group were as good as the Control Group (P>0.05);.the Study Group could significantly decrease TC,LDL-C and FIB levels (P<0.05) ; the TCM symptom effects of the Study Group were better than the Control Group (P <0.05) , and the total efficacy of the 3 months and the 6 months of the Study Group were 73.3% and 86.7% respectively .Conclusion: the Shexiang Baoxin pills have definite effect on the elderly chronic stable angina with hyperlipidemia(XiongBi ,phlegm and blood stasis mixed type) ,and can be proved to decease some risk factors of coronary heart disease.
Objective: To observe the clinical effects of the elderly chronic stable angina with hyperlipidemia treated by the Shexiang Baoxin pills. Methods: 60 cases met the standards of elderly chronic stable angina patients with hyperlipidemia(XiongBi ,phlegm and blood stasis mixed type) were randomly divided into 30 cases of the Control Group and 30 cases of the Study Group. The Control Group was treated with the Isosorbide-5-Mononitrat and Study Group was treated with the Shexiang Baoxin pills .After 3 months and 6 months there should be comparisons between the two groups ,namely ,the improvement of disease effects ,TCM effects ,the nitroglycerin decrease rate and its effects ,the ECG effects and the blood lipid treatment effects ,Hs-CRP and FIB .Results: Clinical observations have shown that the Study Group can significantly improve the 6 months disease treatment effects (P<0.05), and the efficacy of the Study Group was 83.4% ;the 6 months nitroglycerin treatment effects of the Study Group was better than the Control Group(P<0.05) ,the efficacy of the Study Group was 86.7%; the ECG effects of the Study Group were as good as the Control Group (P>0.05);.the Study Group could significantly decrease TC,LDL-C and FIB levels (P<0.05) ; the TCM symptom effects of the Study Group were better than the Control Group (P <0.05) , and the total efficacy of the 3 months and the 6 months of the Study Group were 73.3% and 86.7% respectively .Conclusion: the Shexiang Baoxin pills have definite effect on the elderly chronic stable angina with hyperlipidemia(XiongBi ,phlegm and blood stasis mixed type) ,and can be proved to decease some risk factors of coronary heart disease.
引文
[1]国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组.缺血性心脏病的命名及诊断标准[J].中华心血管病杂志,1981,9(1):75—75.
[2]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390—419.
[3]国家中医药管理局.中药新药临床研究指导原则(试行),北京:中国医药科技出版社, 2002,1:68-77,85-89.
[4]中华心血管杂志编委会心血管药物对策专题组,心血管药物临床实验评价方法的建议[J].中华心血管杂志1998,26(6):405—412.
[5]杜玉花.麝香保心丸治疗冠心病心绞痛的疗效观察[J].社区医学杂志,2009,5:6—7.
[6] Castelli W P. Epidemiology of coronary heart disease:the Framingham study[J].Am J Med,1984,76(2A):4—12.
[7] Wood D,De Backer G,Faergeman O,et a1.Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Social—ties on Coronary Prevention[J].Atherosclerosis,1998,140(2):199—270.
[8] Fruchart J C , Duriez P . HDL and triglyceride as therapeutic targets[J].Curr Opin Lipidol ,2002,13(16):605—616.
[9] LaRosa J C,Hunninghake D,Bush D,et a1.The cholesterol facts.A summary of the evidence relating dietary fats,serum cholesterol,and coronary heart disease.A joint statement by the American Heart Association and the National Heart,Lung,and Blood Institute. The Task Force on Cholesterol Issues,American Heart Association[J].Circulation,1990,81(5):1721—1733.
[10] Topoi E J.Intensive statin therapy—a sea change in cardio—vascular prevention[J].N Engl J Med,2004,350(15):1562—1564.
[11]全国高胆固醇血症控制状况多中心研究协作组.高胆固醇血症临床控制状况多中心协作研究—达标率及影响因素[J].中华心血管病杂志,2002,30(2):109—114.
[12]刘力生.中国高血压治疗现状:控制率低需吸取教训.中国医学论坛报,2006.32(31):31—31.
[13] Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 Subjects with coronary heart disease:The Scandinavian Simvastatin Survival Study(4S)[J].Lancet,1994,344:1383—1389
[14] Shepherd J,Cobbesm,Ford T,ct a1.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia,West of Scotland Co.Dnary Prevention Study Group[J].N Engl J Med,1995,333:1301—1307
[15] The long-term intervention with pravastatin in ischemia disease (LIPID)study group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J]. N.Engl J Med.1998,339:l349—l357
[16] Downs J R,Clearfield M,Weiss,et a1.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels o results of AFCAPS/Tex[J].CAPS,JAMA 1998,279:l6l5—1622
[17]郭纲琬,孙悦平等.麝香和麝香酮毒性及其强心作用的研究[J].药学学报,1980,15(6):281-281.
[18] Mukhopadhyay A et al.Indian J Pharm,1973,35(6):169—169.
[19]陈雪,高兆润.天然麝香研究的概况[J].中草药,1981,12(5):236—236.
[20]沈幼棠.牛黄和麝香的提取物与氢化可的松对缺血心肌作用的比较[J].中国药理学通报,1987,3(1):27—27.
[21]夏炎兴,徐雯燕.天然麝香对培养心肌细胞的作用[J].中草药,1987,18(11):499—502.
[22]高学敏等.中药学,(北京)中国中医药出版社,1987,18(11):499—502.
[23]赵保胜,宓惠卿.冰片对大鼠脑微这内皮细胞ICAM-1表达量的影响[J].中药新药与临床药理,2001,l8(4):332—332.
[24]何晓静,肇丽梅,刘玉兰等.冰片注射液对小鼠实验性脑缺血的保护作用[J].广东药学院学报,2006,22(2):l71—171.
[25]覃仁安,孙学惠,邱德文等.米槁乐滴丸抗心肌缺血作用的实验研究[J].中国药房,l997,8(6):250—250.
[26]江文德.冠心苏合丸能延长小鼠耐缺氧的时间[J].药学学报,1979,14(11):655—655.
[27]朱亮,郭济贤.苏合香抗血栓作用[J].药学学报,1990,12(9):31—31.
[28]周东鹰,齐治实.苏合香成分桂皮酸抗血小板作用的研究(二)[J].北京中医学院学报,1990,13(4):49—49.
[29]赵立波,佟力,赵洪序等.人参总皂甙对心肌缺血再灌注损伤的保护作用实验研究[J].中华胸心血管外科杂志,1994,10(4):353—354.
[30]曾和松,刘正湘.人参皂甙Re对急性缺血再灌注心肌细胞凋亡及fas基因1达的影响[J].华中科技大学学报,2004,33(3):286—288.
[31]田健明,郑淑秋,郭伟芳等.人参皂甙Rg2对大鼠心肌缺血再灌注损伤诱发心肌细胞凋亡的保护作用[J].中国药理学通报,2004,20(4):480—480.
[32]李学军,沈华杰,辛洪波等.三七中人参三醇甙对大鼠离体心肌缺血再灌注损伤及心律失常的保护作用[J].中国药理学与毒理学杂志,1992,6(4):272—274.
[33]高宝英,李学军,刘磊等.三七中人参三醇甙对动物缺血性心律失常影响[J].药学学报,1992,27(9):641—644.
[34]方云祥,李灿,王志纯等.人参总皂甙对犬冠脉流量和血液动力学的影响[J].湖南医科大学学报,1995,20(1):5—8.
[35]徐承水.人参降血脂作用的实验研究[J].长春中医学院学报,2000,16(3):45—46.
[36]郑熙隆,严幼芳.人参茎叶皂甙对家兔慢性高脂血症的脂质调节剂抗过氧化脂质作用[J].中国药理学通报,1991,7(2):110—113.
[37]王斌,张声华.人参总皂甙的耐缺氧效应机理研究[J].食品科学,2002,23(8):271—273.
[38]高学敏.中药学,(北京)中国中医药出版社,1987,18(11):598—599.
[39]王锋,张薇,董红兵.蟾酥的药理研究及其临床应用概况[J].国医论坛,2003,18(5):50—52.
[40] Biek R J,Poindexter B J,Sweney R R,et a1.Effects of Chan Su,a traditional Chinese medicine.on the calcium transients of isolated cardiomyocytes : Cardiotoxicity due to more than Na+ , K+—ATPase blocking[J].Life Sci,2002,72(6):699—709.
[41]苏永华,牛欣.蟾酥制剂的药效作用研究评述[J].北京中医药大学学报,2001,24(2):51-54.
[42]高艳荣,张莉,张磊.蟾酥及其有效成分的药理作用及机制研究进展[J].武警医学院学报,2003,12(5):406—408.
[43]陈一,钟正贤,黄风娇,等.中药肉桂的药理研究(第一报):对血液和心血管系统的影响[J].中药通报,1981,(5):32—32.
[44]袁惠南.培植牛黄药物作用和研究[J].中国中药杂志,1991.16(2):105—108.
[45]杨继凡,韩文华,王淑翠.人工培育牛黄与其它牛黄药理作用的比较[J].中药材科技,1984,(4):4—7.
[46]潘思源等.新一代人工牛黄的药理与毒理学研究:Ⅳ对心血管系统的影响[J].中国生化药物杂志,1994,15(3):172—172
[1]杜玉花.麝香保心丸治疗冠心病心绞痛的疗效观察[J].社区医学杂志,2009,5:6—7.
[2]刘美娜,孙宏鹏,徐威,徐秋月.中国冠心病患者健康生命年损失研究[J].中国公共卫生,2008,24(12):1449—1450.
[3]洪小苏.麝香保心丸治疗动脉粥样硬化性心脏病的临床评价-中西医结合将是我国冠心病防治的趋势[J].中国全科医学,2010,13:62—63.
[4] Fox K.Garcia MA,Ardissino D.et a1.Guidelines on the management of stable angina pectoris:executive summary:the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology[J].Eur Heart J,2006,27(11):1341—138.
[5] Fraker TD Jr,Fjhn SD,Gibbons R J, et a1.2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina : are port of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina[J].J Am Coll Cardiol,2007,50(23):2264—2274.
[6]戴瑞鸿.麝香保心丸的药理及临床应用[J].中国社区医师,2007,23(14):46—46.
[7]吕宝经.麝香保心丸对血管的保护作用[J].中西医结合心脑血管病杂志,2005,3(12):1079一l080.
[8]王大英,李勇,范维琥.麝香保心丸对心肌梗死大鼠梗死面积和血管新生的作用[J].中成药,2004,26(11):912—915.
[9]甘莉,凌燕君,朱丽萍.麝香保心丸治疗轻度高血压合并低密度脂蛋白胆固醇升高患者的体会[J].中成药,2005,27(5):附15—附17.
[10]范维琥.麝香保心丸抑制炎症反应在冠心病治疗中的作用[J].中西医结合心脑血管病杂志,2008,6(5):565—566.
[11]戴瑞鸿.麝香保心丸治疗冠心病研究进展[J].中国社区医师,2004,18:25-26.
[12]叶瑞印,罗彤.麝香保心丸治疗慢性心功能不全的疗效[J].中国中西医结合杂志.2007.1:45—46.
[13]陈献红,李国臣.试析麝香保心丸在冠心病二级预防中的重要地位[J].中国实用医药.2009.4(31):204—205.
[14]张建国,周晓明.3种中成药用于治疗心绞痛的成本一效果分析[J].医学信息.2008.21(9):1603—1606.
[15]陈鹏毅等.麝香保心丸对冠心病心绞痛一氧化氮、一氧化氮合酶、超氧化物歧化酶影响的临床研究[J].河北中医,2005,27(8):618—620.
[16]徐立新,李美,张素燕.麝香保心丸对老年冠心病病人血清E-选择素、P-选择素、SICAM-1、SVCAM-1的影响[J].中药药理与临床,2005,21(1):54—55.
[17]李天奇,李勇,范维琥.麝香保心丸和辛伐他汀对兔股动脉粥样硬化斑块稳定性的影响[J].中华老年心脑血管病杂志,2006,8(5):296—299.
[18]洪永敦,吴辉,赵萍,等.麝香保心丸对颈动脉粥样硬化斑块的影响[J].中国中西医结合杂志,2006,26(9):780—783.
[19]朱莉等.氟伐他汀及麝香保心丸对动脉粥样硬化兔LOX-1表达影响的研究[J].重庆医科大学学报,2008,33增刊1:37—40.
[20]戴瑞鸿.麝香保心丸的作用机理研究进展与临床评价[J].中国社区医师,2005,22(6):26—27.
[21]罗心平,李勇,郭勇力,等.麝香保心丸减少高脂血症对动脉壁损害作用的实验研究[J].中西医结合杂志,1998,18:486—489.
[22]汪姗姗.李勇,范维琥,等.麝香保心丸对鸡胚绒毛尿囊膜及培养的血管内皮细胞的促血管生成作用[J].中国中西医结合杂志,2003,23(2):128—131.
[24]吴剑芸等.麝香保心丸与心达康胶囊治疗老年人急性冠脉综合征的疗效比较[J].中西医结合心脑血管病杂志,2004,2:687—688.
[24]冯培芳等.麝香保心丸防治急性冠脉综合征的临床与实验研究[J].中成药2004,26:23—26.
[25]路世良,李霞丽,原冬亚.麝香保心丸治疗冠心病心绞痛100例[J].中国现代药物应用,2010,4(3):130—130.
[26]高从军.麝香保心丸治疗冠心病心绞痛30例疗效观察[J].首都医药,2010,2(下):42—42.
[27]王臣林,江荣,刘玉杰.麝香保心丸联合通心络胶囊治疗不稳定型心绞痛疗效观察[J].当代医学,2010,16(13):155—155.
[28]万斌.麝香保心丸联合倍他乐克治疗关心病痛40例[J].中国中医急症,2010,19(2):306—307.
[29]朱秀兰等.麝香保心丸治疗心绞痛120例[J].现代中西医结合杂志,2008,17(27):4300—4300.
[30]何扳龙等.麝香保心丸治疗冠心病心绞痛72例疗效观察[J].中国当代医学,2008,16(14):66—67.
[31]马英.麝香保心丸治疗高龄患者冠心病心绞痛疗效观察[J].中国当代医学,2008,6(4):39—39.
[32]吕光.麝香保心丸治疗稳定型心绞痛合并高脂血症43例[J].中国民间疗法,2008,11:32—32.
[33]林威,陈素娟.麝香保心丸对稳定型心绞痛心率、血压的影响[J].福建中医学院报,2008,18(6):6—7.
[34]张平.麝香保心丸治疗冠心病心绞痛并频发期前收缩疗效观察[J].临床心电图学,2009,18(2):101—101.
[35]徐真.麝香保心丸与抗血小板药物合用治疗不稳定性心绞痛的临床观察[J].中华实用中西医杂志,2009,22(24):1801—1801.
[36]李香玉.麝香保心丸联合阿托伐他汀治疗不稳定型心绞痛疗效观察[J].中国医药导报,2009,6(32):39—40.
[2]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390—419.
[3]国家中医药管理局.中药新药临床研究指导原则(试行),北京:中国医药科技出版社, 2002,1:68-77,85-89.
[4]中华心血管杂志编委会心血管药物对策专题组,心血管药物临床实验评价方法的建议[J].中华心血管杂志1998,26(6):405—412.
[5]杜玉花.麝香保心丸治疗冠心病心绞痛的疗效观察[J].社区医学杂志,2009,5:6—7.
[6] Castelli W P. Epidemiology of coronary heart disease:the Framingham study[J].Am J Med,1984,76(2A):4—12.
[7] Wood D,De Backer G,Faergeman O,et a1.Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Social—ties on Coronary Prevention[J].Atherosclerosis,1998,140(2):199—270.
[8] Fruchart J C , Duriez P . HDL and triglyceride as therapeutic targets[J].Curr Opin Lipidol ,2002,13(16):605—616.
[9] LaRosa J C,Hunninghake D,Bush D,et a1.The cholesterol facts.A summary of the evidence relating dietary fats,serum cholesterol,and coronary heart disease.A joint statement by the American Heart Association and the National Heart,Lung,and Blood Institute. The Task Force on Cholesterol Issues,American Heart Association[J].Circulation,1990,81(5):1721—1733.
[10] Topoi E J.Intensive statin therapy—a sea change in cardio—vascular prevention[J].N Engl J Med,2004,350(15):1562—1564.
[11]全国高胆固醇血症控制状况多中心研究协作组.高胆固醇血症临床控制状况多中心协作研究—达标率及影响因素[J].中华心血管病杂志,2002,30(2):109—114.
[12]刘力生.中国高血压治疗现状:控制率低需吸取教训.中国医学论坛报,2006.32(31):31—31.
[13] Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 Subjects with coronary heart disease:The Scandinavian Simvastatin Survival Study(4S)[J].Lancet,1994,344:1383—1389
[14] Shepherd J,Cobbesm,Ford T,ct a1.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia,West of Scotland Co.Dnary Prevention Study Group[J].N Engl J Med,1995,333:1301—1307
[15] The long-term intervention with pravastatin in ischemia disease (LIPID)study group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J]. N.Engl J Med.1998,339:l349—l357
[16] Downs J R,Clearfield M,Weiss,et a1.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels o results of AFCAPS/Tex[J].CAPS,JAMA 1998,279:l6l5—1622
[17]郭纲琬,孙悦平等.麝香和麝香酮毒性及其强心作用的研究[J].药学学报,1980,15(6):281-281.
[18] Mukhopadhyay A et al.Indian J Pharm,1973,35(6):169—169.
[19]陈雪,高兆润.天然麝香研究的概况[J].中草药,1981,12(5):236—236.
[20]沈幼棠.牛黄和麝香的提取物与氢化可的松对缺血心肌作用的比较[J].中国药理学通报,1987,3(1):27—27.
[21]夏炎兴,徐雯燕.天然麝香对培养心肌细胞的作用[J].中草药,1987,18(11):499—502.
[22]高学敏等.中药学,(北京)中国中医药出版社,1987,18(11):499—502.
[23]赵保胜,宓惠卿.冰片对大鼠脑微这内皮细胞ICAM-1表达量的影响[J].中药新药与临床药理,2001,l8(4):332—332.
[24]何晓静,肇丽梅,刘玉兰等.冰片注射液对小鼠实验性脑缺血的保护作用[J].广东药学院学报,2006,22(2):l71—171.
[25]覃仁安,孙学惠,邱德文等.米槁乐滴丸抗心肌缺血作用的实验研究[J].中国药房,l997,8(6):250—250.
[26]江文德.冠心苏合丸能延长小鼠耐缺氧的时间[J].药学学报,1979,14(11):655—655.
[27]朱亮,郭济贤.苏合香抗血栓作用[J].药学学报,1990,12(9):31—31.
[28]周东鹰,齐治实.苏合香成分桂皮酸抗血小板作用的研究(二)[J].北京中医学院学报,1990,13(4):49—49.
[29]赵立波,佟力,赵洪序等.人参总皂甙对心肌缺血再灌注损伤的保护作用实验研究[J].中华胸心血管外科杂志,1994,10(4):353—354.
[30]曾和松,刘正湘.人参皂甙Re对急性缺血再灌注心肌细胞凋亡及fas基因1达的影响[J].华中科技大学学报,2004,33(3):286—288.
[31]田健明,郑淑秋,郭伟芳等.人参皂甙Rg2对大鼠心肌缺血再灌注损伤诱发心肌细胞凋亡的保护作用[J].中国药理学通报,2004,20(4):480—480.
[32]李学军,沈华杰,辛洪波等.三七中人参三醇甙对大鼠离体心肌缺血再灌注损伤及心律失常的保护作用[J].中国药理学与毒理学杂志,1992,6(4):272—274.
[33]高宝英,李学军,刘磊等.三七中人参三醇甙对动物缺血性心律失常影响[J].药学学报,1992,27(9):641—644.
[34]方云祥,李灿,王志纯等.人参总皂甙对犬冠脉流量和血液动力学的影响[J].湖南医科大学学报,1995,20(1):5—8.
[35]徐承水.人参降血脂作用的实验研究[J].长春中医学院学报,2000,16(3):45—46.
[36]郑熙隆,严幼芳.人参茎叶皂甙对家兔慢性高脂血症的脂质调节剂抗过氧化脂质作用[J].中国药理学通报,1991,7(2):110—113.
[37]王斌,张声华.人参总皂甙的耐缺氧效应机理研究[J].食品科学,2002,23(8):271—273.
[38]高学敏.中药学,(北京)中国中医药出版社,1987,18(11):598—599.
[39]王锋,张薇,董红兵.蟾酥的药理研究及其临床应用概况[J].国医论坛,2003,18(5):50—52.
[40] Biek R J,Poindexter B J,Sweney R R,et a1.Effects of Chan Su,a traditional Chinese medicine.on the calcium transients of isolated cardiomyocytes : Cardiotoxicity due to more than Na+ , K+—ATPase blocking[J].Life Sci,2002,72(6):699—709.
[41]苏永华,牛欣.蟾酥制剂的药效作用研究评述[J].北京中医药大学学报,2001,24(2):51-54.
[42]高艳荣,张莉,张磊.蟾酥及其有效成分的药理作用及机制研究进展[J].武警医学院学报,2003,12(5):406—408.
[43]陈一,钟正贤,黄风娇,等.中药肉桂的药理研究(第一报):对血液和心血管系统的影响[J].中药通报,1981,(5):32—32.
[44]袁惠南.培植牛黄药物作用和研究[J].中国中药杂志,1991.16(2):105—108.
[45]杨继凡,韩文华,王淑翠.人工培育牛黄与其它牛黄药理作用的比较[J].中药材科技,1984,(4):4—7.
[46]潘思源等.新一代人工牛黄的药理与毒理学研究:Ⅳ对心血管系统的影响[J].中国生化药物杂志,1994,15(3):172—172
[1]杜玉花.麝香保心丸治疗冠心病心绞痛的疗效观察[J].社区医学杂志,2009,5:6—7.
[2]刘美娜,孙宏鹏,徐威,徐秋月.中国冠心病患者健康生命年损失研究[J].中国公共卫生,2008,24(12):1449—1450.
[3]洪小苏.麝香保心丸治疗动脉粥样硬化性心脏病的临床评价-中西医结合将是我国冠心病防治的趋势[J].中国全科医学,2010,13:62—63.
[4] Fox K.Garcia MA,Ardissino D.et a1.Guidelines on the management of stable angina pectoris:executive summary:the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology[J].Eur Heart J,2006,27(11):1341—138.
[5] Fraker TD Jr,Fjhn SD,Gibbons R J, et a1.2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina : are port of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina[J].J Am Coll Cardiol,2007,50(23):2264—2274.
[6]戴瑞鸿.麝香保心丸的药理及临床应用[J].中国社区医师,2007,23(14):46—46.
[7]吕宝经.麝香保心丸对血管的保护作用[J].中西医结合心脑血管病杂志,2005,3(12):1079一l080.
[8]王大英,李勇,范维琥.麝香保心丸对心肌梗死大鼠梗死面积和血管新生的作用[J].中成药,2004,26(11):912—915.
[9]甘莉,凌燕君,朱丽萍.麝香保心丸治疗轻度高血压合并低密度脂蛋白胆固醇升高患者的体会[J].中成药,2005,27(5):附15—附17.
[10]范维琥.麝香保心丸抑制炎症反应在冠心病治疗中的作用[J].中西医结合心脑血管病杂志,2008,6(5):565—566.
[11]戴瑞鸿.麝香保心丸治疗冠心病研究进展[J].中国社区医师,2004,18:25-26.
[12]叶瑞印,罗彤.麝香保心丸治疗慢性心功能不全的疗效[J].中国中西医结合杂志.2007.1:45—46.
[13]陈献红,李国臣.试析麝香保心丸在冠心病二级预防中的重要地位[J].中国实用医药.2009.4(31):204—205.
[14]张建国,周晓明.3种中成药用于治疗心绞痛的成本一效果分析[J].医学信息.2008.21(9):1603—1606.
[15]陈鹏毅等.麝香保心丸对冠心病心绞痛一氧化氮、一氧化氮合酶、超氧化物歧化酶影响的临床研究[J].河北中医,2005,27(8):618—620.
[16]徐立新,李美,张素燕.麝香保心丸对老年冠心病病人血清E-选择素、P-选择素、SICAM-1、SVCAM-1的影响[J].中药药理与临床,2005,21(1):54—55.
[17]李天奇,李勇,范维琥.麝香保心丸和辛伐他汀对兔股动脉粥样硬化斑块稳定性的影响[J].中华老年心脑血管病杂志,2006,8(5):296—299.
[18]洪永敦,吴辉,赵萍,等.麝香保心丸对颈动脉粥样硬化斑块的影响[J].中国中西医结合杂志,2006,26(9):780—783.
[19]朱莉等.氟伐他汀及麝香保心丸对动脉粥样硬化兔LOX-1表达影响的研究[J].重庆医科大学学报,2008,33增刊1:37—40.
[20]戴瑞鸿.麝香保心丸的作用机理研究进展与临床评价[J].中国社区医师,2005,22(6):26—27.
[21]罗心平,李勇,郭勇力,等.麝香保心丸减少高脂血症对动脉壁损害作用的实验研究[J].中西医结合杂志,1998,18:486—489.
[22]汪姗姗.李勇,范维琥,等.麝香保心丸对鸡胚绒毛尿囊膜及培养的血管内皮细胞的促血管生成作用[J].中国中西医结合杂志,2003,23(2):128—131.
[24]吴剑芸等.麝香保心丸与心达康胶囊治疗老年人急性冠脉综合征的疗效比较[J].中西医结合心脑血管病杂志,2004,2:687—688.
[24]冯培芳等.麝香保心丸防治急性冠脉综合征的临床与实验研究[J].中成药2004,26:23—26.
[25]路世良,李霞丽,原冬亚.麝香保心丸治疗冠心病心绞痛100例[J].中国现代药物应用,2010,4(3):130—130.
[26]高从军.麝香保心丸治疗冠心病心绞痛30例疗效观察[J].首都医药,2010,2(下):42—42.
[27]王臣林,江荣,刘玉杰.麝香保心丸联合通心络胶囊治疗不稳定型心绞痛疗效观察[J].当代医学,2010,16(13):155—155.
[28]万斌.麝香保心丸联合倍他乐克治疗关心病痛40例[J].中国中医急症,2010,19(2):306—307.
[29]朱秀兰等.麝香保心丸治疗心绞痛120例[J].现代中西医结合杂志,2008,17(27):4300—4300.
[30]何扳龙等.麝香保心丸治疗冠心病心绞痛72例疗效观察[J].中国当代医学,2008,16(14):66—67.
[31]马英.麝香保心丸治疗高龄患者冠心病心绞痛疗效观察[J].中国当代医学,2008,6(4):39—39.
[32]吕光.麝香保心丸治疗稳定型心绞痛合并高脂血症43例[J].中国民间疗法,2008,11:32—32.
[33]林威,陈素娟.麝香保心丸对稳定型心绞痛心率、血压的影响[J].福建中医学院报,2008,18(6):6—7.
[34]张平.麝香保心丸治疗冠心病心绞痛并频发期前收缩疗效观察[J].临床心电图学,2009,18(2):101—101.
[35]徐真.麝香保心丸与抗血小板药物合用治疗不稳定性心绞痛的临床观察[J].中华实用中西医杂志,2009,22(24):1801—1801.
[36]李香玉.麝香保心丸联合阿托伐他汀治疗不稳定型心绞痛疗效观察[J].中国医药导报,2009,6(32):39—40.